SC
PRLD icon

Steven Cohen’s Prelude Therapeutics PRLD Stock Holding History

Steven Cohen’s Portfolio PRLD Stock Details PRLD Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		– Sell
-16,329
Closed -$55.8K – 4467
2026
Q1 		$55.8K Sell
16,329
-42,839
-72% -$112K ﹤0.01% 3655
2025
Q4 		$172K Buy
+59,168
New +$99.8K ﹤0.01% 3669
2023
Q2 		– Sell
-1,222
Closed -$6.96K – 2664
2023
Q1 		$6.96K Buy
+1,222
New +$7.45K ﹤0.01% 2062
2020
Q4 		– Sell
-155,690
Closed -$4.69M – 1087
2020
Q3 		$4.69M Buy
+155,690
New +$4.4M 0.02% 579

Other funds holding PRLD

O
OrbiMed New York $5.4B AUM 163.13% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return
SCM
Soleus Capital Management Greenwich, Connecticut $2.9B AUM 169.69% 1-Year Est. Return
KCM
Kynam Capital Management Princeton, New Jersey $1.81B AUM 192.15% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
SFM
Sphera Funds Management Tel Aviv, Israel $767M AUM 119.71% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return
ACM
ADAR1 Capital Management Austin, Texas $2.19B AUM 374.99% 1-Year Est. Return

Steven Cohen's PRLD Position: Q2 2026 in Review

Steven Cohen sold out of Prelude Therapeutics (PRLD) in Q2 2026, closing a stake of 16,329 shares — an estimated $55.8K sold.

Steven Cohen first reported a position in PRLD in Q3 2020 and held it in 4 quarters. The position peaked at $4.69M in Q3 2020. 75 funds tracked by Wall St. Rank hold PRLD as of Q2 2026.

  • Steven Cohen reported no remaining Prelude Therapeutics position as of Q2 2026 after selling out during the quarter.
  • Steven Cohen sold 16,329 Prelude Therapeutics shares in Q2 2026, an estimated $55.8K.
  • Steven Cohen first reported a position in Prelude Therapeutics in Q3 2020 and held it in 4 quarters.
  • Steven Cohen's Prelude Therapeutics position peaked at $4.69M in Q3 2020.
  • 75 funds tracked by Wall St. Rank held Prelude Therapeutics as of Q2 2026.

Based on Point72 Asset Management's 13F filing for Q2 2026, filed 14 Aug 2026.